Clinical trial · Interventional
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
Phase II Study of Bryostatin-1 in Metastatic Renal Cell Carcinoma(Summary Last Modified 8/1999)
NCT00003968CI-TRIAL-00009380completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have metastatic kidney cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bryostatin 1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
- interventionNames
- Drug: bryostatin 1
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed metastatic renal cell carcinoma * Bidimensionally measurable disease * Clear evidence of progression if only site of measurable disease is within previous radiation port * Previously irradiated brain metastases allowed, if not life threatening, symptoms controlled for 3 months, and not requiring corticosteroids PATIENT CHARACTERISTICS: * Age: 18 and over * Performance status: ECOG 0-1 * Life expectancy: Greater than 3 months * WBC at least 3,000/mm3 * Platelet count at least 100,00/mm3 * Bilirubin no greater than 1.5 mg/dL * Creatinine no greater than 2.0 mg/dL OR creatinine clearance greater than 50 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception for 1 month before, during, and for 3 months after study * No active bacterial or viral infection * No serious underlying medical condition that would interfere with compliance * No other malignancy within the past 5 years except basal cell carcinoma of the skin * No dementia or altered mental status that would prevent informed consent PRIOR CONCURRENT THERAPY: * No more than 1 prior therapy with biologic response modifiers * No prior chemotherapy for advanced disease * No other concurrent chemotherapy * No concurrent steriods (except topical use) * At least 4 weeks since prior radiotherapy * No concurrent radiotherapy * At least 4 weeks since major surgery (including nephrectomy) * No other concurrent experimental agents
References
Publications (0)
Data not yet available
No reference posted for this study.